Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Phase II, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Pertuzumab and Herceptin (Trastuzumab) in Patients With HER2-Positive Metastatic Breast Cancer

NCT01674062 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01674062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01674062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Phase II, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Pertuzumab and Herceptin (Trastuzumab) in Patients With HER2-Positive Metastatic Breast Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2006
Completion date
September 30, 2015
Enrollment
95 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer